Microneedles for treatment of peanut allergy

花生过敏治疗针 花生过敏是一种危及生命的疾病。大约1%的美国人口（约300万人）有花生 过敏而且没有FDA批准的治疗方法严格避免，无花生饮食是唯一的选择 可用于管理花生过敏，这对患者的生活方式及其 家庭，并可能导致营养不良。该提案的总体目标是开发一种涂层 用于花生过敏的基于微针（MN）的皮肤免疫疗法（CIT），也称为（MNs-CIT）。目前 花生口服免疫疗法受到了广泛关注。然而，口服免疫疗法的一个主要局限性是 花生的口服剂量增加到数千毫克，这会引起不良反应。基于我们 我们的假设是，涂有花生过敏原的MN可以安全地将花生过敏原输送到 产生持久的花生脱敏。我们的具体目标是：（一）发展体育- 包衣MN并评价它们在治疗花生过敏中的短期和长期治疗效果，（ii） 表征花生MNs-CIT的机制，以及（iii）评估新生猪模型中的治疗功效 花生过敏 如果成功的话，这些研究将为开发一种新的更安全的花生提供基础。 过敏免疫治疗

Microneedles for treatment of peanut allergy Peanut allergy is a life-threatening condition. About 1% of the US population (~3 million people) has peanut allergies, and there is no FDA-approved treatment. Strict avoidance, and a peanut-free diet is the only option available to manage peanut allergies, which imposes severe limitations on the lifestyle of the patient and their families, and can lead to nutritional deficiencies. The overall goal of this proposal is to develop a coated microneedles (MNs) based cutaneous immunotherapy (CIT) a.k.a (MNs-CIT) for peanut allergy. Presently peanut oral immunotherapy has received much attention. However, a major limitation of oral immunotherapy is that the peanut oral dose is escalated to thousands of milligrams, which causes adverse effects. Based on our preliminary data our hypothesis is that MNs coated with peanut allergen can safely deliver peanut allergen in to the superficial skin-layer to produce long-lasting peanut desensitization. Our specific aims are: (i) Develop PE- coated MNs and evaluate their short and long term therapeutic effectiveness in treating peanut allergy, (ii) Characterize the mechanism of peanut MNs-CIT, and (iii) Evaluate therapeutic efficacy in a neonatal pig model of peanut allergy. If successful, these studies will provide the foundation to support the development of a novel and safer peanut allergy immunotherapy treatment.